首页> 外文OA文献 >Lapatinib, a Dual EGFR and HER2 Kinase Inhibitor, Selectively Inhibits HER2-Amplified Human Gastric Cancer Cells and is Synergistic with Trastuzumab In vitro and In vivo

【2h】

Lapatinib, a Dual EGFR and HER2 Kinase Inhibitor, Selectively Inhibits HER2-Amplified Human Gastric Cancer Cells and is Synergistic with Trastuzumab In vitro and In vivo

机译：Lapatinib，双EGFR和HER2激酶抑制剂，有选择性地抑制HER2-扩增的人胃癌细胞，并在体外和体内与曲妥珠单抗协同作用

代理获取

本网站仅为用户提供外文OA文献查询和代理获取服务，本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文，但由于OA文献来源多样且变更频繁，仍可能出现获取不到、文献不完整或与标题不符等情况，如果获取不到我们将提供退款服务。请知悉。

页面导航

著录项
引文网络
相似文献
相关主题

著录项

作者
Zev A. Wainberg; Adrian Anghel; Amrita J. Desai; Raul Ayala; Tong Luo; Brent Safran; Marlena S. Fejzo; J. Randolph Hecht; Dennis J. Slamon; Richard S. Finn;
展开▼
作者单位

展开▼
年度 2010
总页数
原文格式 PDF
正文语种
中图分类

相似文献

外文文献
中文文献
专利

1. Lapatinib, a dual EGFR and HER2 kinase inhibitor, selectively inhibits HER2-amplified human gastric cancer cells and is synergistic with trastuzumab in vitro and in vivo. [J] . Wainberg ZA, Anghel A, Desai A Clinical cancer research: an official journal of the American Association for Cancer Research . 2010,第5期

机译：拉帕替尼是EGFR和HER2激酶的双重抑制剂，可选择性抑制HER2扩增的人胃癌细胞，并在体外和体内与曲妥珠单抗协同作用。
2. Dacomitinib (PF-00299804), an irreversible Pan-HER inhibitor, inhibits proliferation of HER2-amplified breast cancer cell lines resistant to trastuzumab and lapatinib [J] . KalousO., ConklinD., DesaiA.J., Molecular cancer therapeutics . 2012,第9期

机译：达可替尼（PF-00299804），一种不可逆的Pan-HER抑制剂，抑制对曲妥珠单抗和拉帕替尼产生抗药性的HER2扩增乳腺癌细胞系的增殖
3. Lapatinib, a Dual-Targeted Small Molecule Inhibitor of Egfr and Her2, in Her2-Amplified Breast Cancer: From Bench to Bedside [J] . Roger Y. Tsang, Saeed Sadeghi, Richard S. Finn Clinical Medicine Insights: Therapeutics . 2011,第3期

机译：拉帕替尼，Erfr和Her2的双重靶向小分子抑制剂，在Her2扩增乳腺癌中的作用：从实验台到床边
4. Combination of Novel HER2 Targeting Antibody 1A12 with Trastuzumab Shows Synergistic Antitumor Activity in HER2 Positive Gastric Cancer [C] . Kyu-Tae Kim, Jong-Seo Lee, Ki-Hyun Kim, PEGS . 2015

机译：具有曲妥珠单抗的新型HER2靶向抗体1a12的组合在HER2阳性胃癌中显示了协同抗肿瘤活性
5. Targeting EGFR and ErbB2 by small molecule tyrosine kinase inhibitors in human colon cancer. [D] . Zhou, Yunfei. 2005

机译：小分子酪氨酸激酶抑制剂在人结肠癌中靶向EGFR和ErbB2。
6. Activity of lapatinib a novel HER2 and EGFR dual kinase inhibitor in human endometrial cancer cells [O] . G E Konecny, N Venkatesan, G Yang, 2008

机译：拉帕替尼（一种新型HER2和EGFR双激酶抑制剂）在人子宫内膜癌细胞中的活性
7. Dacomitinib (PF-00299804), an Irreversible Pan-HER Inhibitor, Inhibits Proliferation of HER2-Amplified Breast Cancer Cell Lines Resistant to Trastuzumab and Lapatinib [O] . Ondrej Kalous, Dylan Conklin, Amrita J. Desai, 2012

机译：Dacomitinib（PF-00299804），一种不可逆的泛抑制剂，抑制了耐血管Zumab和Lapatinib的HER2扩增的乳腺癌细胞系的增殖

Lapatinib, a Dual EGFR and HER2 Kinase Inhibitor, Selectively Inhibits HER2-Amplified Human Gastric Cancer Cells and is Synergistic with Trastuzumab In vitro and In vivo

著录项

引文网络

相似文献

相关主题

期刊订阅